.png){kind=icon}
-
Cell and Gene Therapies - How Prepared is Europe?
White PapersAug. 01, 2020
Cell and gene therapies promise a potentially life-long cure for many rare diseases and cancers. However, despite centralized regulatory approval, high costs and long-term clinical uncertainty have resulted in variable patient access across Europe. This white paper seeks to assess how prepared Europe markets are for cell and gene therapies and compare the 'preparedness' of these markets via a scoring system that considers key indicators and categorizes them into three equally weighted components: Budget and infrastructure, finance, reimbursement and implementation and HTA and pricing processes.
Cell and gene therapies promise a potentially life-long cure for many rare diseases and cancers. However, despite centralized regulatory approval, high costs and long-term clinical uncertainty have resulted in variable patient access across Europe. This white paper seeks to assess how prepared Europe markets are for cell and gene therapies and compare the 'preparedness' of these markets via a scoring system that considers key indicators and categorizes them into three equally weighted components: Budget and infrastructure, finance, reimbursement and implementation and HTA and pricing processes.
